ClinicalTrials.Veeva
Menu

Find clinical trials for Alzheimer's Disease in Paris, Île-de-France

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Alzheimer Disease
Dementia
Cognitive Dysfunction
Mental Disorders
Brain Diseases
Nervous System Diseases
Neurocognitive Disorders

Alzheimer's Disease trials near Paris, Île-de-France, FRA:

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)

To assess the safety, tolerability, biomarker, cognitive, and clinical efficacy of investigational products in participants with an Alzheimer's...

Enrolling
Alzheimers Disease
Alzheimers Disease, Familial
Drug: Lecanemab
Drug: E2814

Phase 2, Phase 3

The Washington University
The Washington University

Paris cedex 13, Paris, France and 37 other locations

efficacy of investigational products in participants with an Alzheimer's disease-causing mutation by determining if treatment with ...

Enrolling
Alzheimers Disease
Alzheimers Disease, Familial
Drug: Solanezumab
Drug: Lecanemab

Phase 2, Phase 3

The Washington University
The Washington University

Paris cedex 13, Paris, France and 38 other locations

Recently updated

versus (vs) placebo on the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) up to Week 80 in study participants with prodromal or mild Alzheimer's...

Active, not recruiting
Alzheimer's Disease
Other: Placebo
Biological: Bepranemab

Phase 2

UCB
UCB

Paris, France and 101 other locations

be from 2 clinical subgroups: mild cognitive impairment (MCI) due to Alzheimer's disease (AD) or mild Alzheimer's disease...

Active, not recruiting
Alzheimer's Disease
Drug: Lecanemab 2.5 mg/kg
Drug: Lecanemab 10 mg/kg

Phase 2

Eisai
Eisai

Paris, France and 168 other locations

This study will be conducted to evaluate the efficacy of lecanemab in participants with early Alzheimer's disease (EAD) by determin...

Active, not recruiting
Early Alzheimer's Disease
Drug: Lecanemab
Drug: Placebo

Phase 3

Eisai
Eisai

Paris cedex 10, Paris, France and 246 other locations

administered once every four weeks (Q4W) in slowing cognitive and functional decline as compared to placebo in participants with early Alzheimer's...

Enrolling
Alzheimer Disease
Drug: ACU193
Drug: Placebo

Phase 2, Phase 3

Acumen Pharmaceuticals

Paris, France and 124 other locations

The aim of this study is to assess the efficacy and safety of GSK4527226 in participants with early Alzheimer's Disease (AD) (inclu...

Enrolling
Alzheimer's Disease
Other: Placebo
Drug: GSK4527226

Phase 2

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Paris, France and 103 other locations

This proof-of-concept study will assess safety, tolerance, and efficacy of NanoLithium® NP03 in patients with mild-to-severe Alzheimer's Disease...

Enrolling
Alzheimer's Disease
Drug: NanoLithium® NP03
Drug: Placebo

Phase 2

Medesis Pharma

Paris, France and 7 other locations

Status recently updated

This study aims to analyse, in vivo, the interplay between microglial activation and tau pathology in Alzheimer's disease (AD) usin...

Not yet enrolling
Enrolling
Alzheimer Disease
Radiation: [18F]-DPA-714
Radiation: [11C]-UCB-J
Centre Hospitalier St Anne

Paris, France and 2 other locations

A phase 2 randomized, double blind, placebo controlled study evaluating the efficacy and safety of AL002 in participants with Early Alzheimer's...

Active, not recruiting
Alzheimer Disease
Drug: Placebo
Drug: AL002

Phase 2

Alector

Paris, France and 91 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems